Compare GSK plc (GSK) vs JPMorgan Diversified Return International Eqty ETF (JPIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs JPMorgan Diversified Return International Eqty ETF — how do they compare? GSK plc trades at $46.54 (market cap $91.88B), while JPMorgan Diversified Return International Eqty ETF trades at $73.01 (market cap $378.77M). The key difference: GSK plc is far larger — about 242.6× JPMorgan Diversified Return International Eqty ETF's market cap, and GSK plc pays a 3.9% dividend while JPMorgan Diversified Return International Eqty ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and JPMorgan Diversified Return International Eqty ETF for 120 Days on average.
| GSK | JPIN | |
|---|---|---|
Market Cap | $91.88B | $378.77M |
Volume | 7,730,529 | 13,861 |
Sector | Health | — |
52-Week High | $61.18 | $77.80 |
52-Week Low | $43.24 | $64.96 |
Typical Hold Time | 93 Days | 120 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
JPIN trades at $73.03 with minimal daily movement (+0.12%). Technical indicators signal strong bearish momentum across moving averages and oscillators, though RSI levels suggest potential oversold conditions. The ETF maintains a strategic focus on international value stocks but lacks current fundamental ratio data. Recent dividend activity shows a $0.51 distribution scheduled for September 2026.
The bearish technical setup dominates the near-term outlook, with resistance clustered at $74. Investment appeal hinges on international equity market recovery and the ETF's value strategy execution. Key risks include global market volatility and currency fluctuations affecting international holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →
